Lupin share price
NSE: LUPINPharma & HealthcareDrug Manufacturers - Specialty & Generic
Lupin at a glance
Lupin (NSE: LUPIN) closed at ₹1,930.00 on 19 Oct 2026, down 1.83% on the day. With a market capitalisation of ₹88,246 Cr, it ranks 124th by market cap among the 4,183 NSE companies Pivot tracks (a mid-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.
At its last close the stock traded at 16.6× trailing earnings, against a return on equity of 23.8% in FY26. Over the past year the share price has fallen 1.5%. Its 52-week range is ₹1,900.00 (28 Oct 2025) to ₹2,529.50 (16 Jul 2026); the last close is 23.7% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹5,755 Cr (+17.8% year on year) and net profit ₹528 Cr (+27.0%), on a consolidated basis. Promoters held 46.85% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹88,246 CrRank 124 on NSE
- P/E (trailing)
- 16.6×
- Price to book
- 4.71×FY26
- EPS (TTM)
- ₹46.01to Q1 FY27
- ROE
- 23.8%FY26
- ROCE
- 30.6%FY26
- Debt to equity
- 0.26FY26
- Net profit margin
- 19.2%FY26
- Book value / share
- ₹490.99FY26
- Dividend payout
- 10.3%FY26
- 52-week high
- ₹2,529.5016 Jul 2026
- 52-week low
- ₹1,900.0028 Oct 2025
- 1-year return
- −1.5%
- RSI (14-day)
- 30.8
Returns to 19 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | −1.83% | −0.3% | −7.6% | −22.4% | −1.5% |
Lupin quarterly results
| Quarter | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹4,157 Cr | ₹4,657 Cr | ₹4,217 Cr | ₹4,883 Cr | ₹4,818 Cr | ₹5,345 Cr | ₹5,028 Cr | ₹5,755 Cr |
| Revenue YoY | +39.4% | +34.3% | +27.9% | +19.0% | +15.9% | +14.8% | +19.2% | +17.8% |
| Net profit | ₹329 Cr | ₹470 Cr | ₹313 Cr | ₹415 Cr | ₹375 Cr | ₹498 Cr | ₹429 Cr | ₹528 Cr |
| Net profit YoY | +62.5% | +37.9% | −53.3% | +23.8% | +13.7% | +5.9% | +37.2% | +27.0% |
| Net margin | 7.9% | 10.1% | 7.4% | 8.5% | 7.8% | 9.3% | 8.5% | 9.2% |
| EPS | ₹9.53 | ₹13.99 | ₹8.95 | ₹12.09 | ₹10.60 | ₹14.42 | ₹11.26 | ₹9.73 |
Lupin financials
| Item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Revenue | ₹15,163 Cr | ₹16,405 Cr | ₹16,642 Cr | ₹20,011 Cr | ₹22,708 Cr | — |
| Operating profit | ₹1,675 Cr | −₹1,373 Cr | ₹716 Cr | ₹2,422 Cr | ₹4,015 Cr | — |
| Net profit | ₹1,227 Cr | −₹1,510 Cr | ₹448 Cr | ₹1,936 Cr | ₹3,306 Cr | — |
| EPS (₹) | ₹27.00 | −₹34.00 | ₹9.00 | ₹42.00 | ₹72.00 | — |
| Cash from operations | ₹1,822 Cr | ₹367 Cr | ₹1,897 Cr | ₹3,648 Cr | ₹3,000 Cr | — |
| Total debt | ₹16 Cr | ₹142 Cr | ₹28 Cr | ₹0 Cr | ₹1,766 Cr | ₹1,643 Cr |
| Shareholders' equity | ₹13,803 Cr | ₹12,153 Cr | ₹12,465 Cr | ₹14,290 Cr | ₹17,204 Cr | ₹22,448 Cr |
Lupin shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 46.92% | 46.90% | 46.90% | 46.89% | 46.86% | 46.85% |
| Foreign institutions | 21.46% | 21.25% | 20.49% | 21.49% | 21.71% | 22.42% |
| Domestic institutions | 25.41% | 25.56% | 26.55% | 25.58% | 25.32% | 24.65% |
| Non-institutions | 6.20% | 6.28% | 6.06% | 6.03% | 6.11% | 6.08% |
Lupin vs peers
The listed Pharma & Healthcare companies nearest to Lupin by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| APOLLOHOSPApollo Hospitals Enterprise | ₹7,695.00 | −1.75% | +0.1% | ₹1,10,642 Cr | 57 | — |
| CIPLACipla | ₹1,324.00 | −0.12% | −15.6% | ₹1,06,959 Cr | 27.5 | — |
| DRREDDYDr. Reddy's Laboratories | ₹1,241.20 | +0.89% | −1.8% | ₹1,03,600 Cr | — | — |
| AUROPHARMAAurobindo Pharma | ₹1,617.00 | −2.54% | +43.1% | ₹93,039 Cr | 26.8 | — |
| MANKINDMankind Pharma | ₹2,251.00 | −1.11% | −8.5% | ₹92,965 Cr | 48.7 | — |
| LUPINLupin | ₹1,930.00 | −1.83% | −1.5% | ₹88,246 Cr | 16.6 | — |
| MAXHEALTHMax Healthcare Institute | ₹830.00 | −1.98% | −28.2% | ₹80,779 Cr | 56.3 | — |
Ask anything about Lupin
Pivot answers on the live chart with evidence you can check, and tests strategies against LUPIN's own history. Try: “Why has LUPIN moved over the last three months?” · “Backtest a 50-day moving-average crossover on LUPIN over five years” · “Compare LUPIN with APOLLOHOSP on margins and valuation”
Frequently asked questions about Lupin
What is the share price of Lupin today?
Lupin (NSE: LUPIN) last closed at ₹1,930.00 on 19 Oct 2026. Its 52-week high is ₹2,529.50 and its 52-week low is ₹1,900.00.
What is the market cap of Lupin?
Lupin's market capitalisation is ₹88,246 Cr (₹88,246 Cr) at the 19 Oct 2026 close, ranking 124th among the NSE companies Pivot tracks.
What is the P/E ratio of Lupin?
Lupin trades at a trailing P/E of 16.6. The median P/E of the 5 closest Pharma & Healthcare peers by market cap is 48.7.
What is the ROE and ROCE of Lupin?
Return on equity was 23.8% in FY26 and return on capital employed was 30.6% in FY26 (consolidated figures).
Is Lupin a debt-free company?
No. Lupin's debt-to-equity ratio was 0.26 in FY26, with total debt of ₹1,643 Cr.
What were Lupin's latest quarterly results?
For Q1 FY27 (quarter ended 30 Jun 2026), Lupin reported revenue of ₹5,755 Cr, +17.8% year on year, and net profit of ₹528 Cr, +27.0% year on year.
How has Lupin stock performed over the last year?
Lupin's share price has fallen 1.5% over the past year, −22.4% over three months and −7.6% over one month, to the 19 Oct 2026 close.
What is the shareholding pattern of Lupin?
As of 30 Jun 2026: promoters 46.85%, foreign institutions 22.42%, domestic institutions 24.65%, non-institutions 6.08%.
Who are Lupin's competitors?
The listed Pharma & Healthcare companies closest to Lupin by market cap are Apollo Hospitals Enterprise, Cipla, Dr. Reddy's Laboratories, Aurobindo Pharma, Mankind Pharma and Max Healthcare Institute.
Is Lupin a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Lupin's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on LUPIN against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 19 Oct 2026 (returns and ratios at the 19 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with L · all NSE stocks · this page as text